JP6882191B2 - 神経保護および神経変性の治療のための組成物および方法 - Google Patents

神経保護および神経変性の治療のための組成物および方法 Download PDF

Info

Publication number
JP6882191B2
JP6882191B2 JP2017555718A JP2017555718A JP6882191B2 JP 6882191 B2 JP6882191 B2 JP 6882191B2 JP 2017555718 A JP2017555718 A JP 2017555718A JP 2017555718 A JP2017555718 A JP 2017555718A JP 6882191 B2 JP6882191 B2 JP 6882191B2
Authority
JP
Japan
Prior art keywords
composition
creatine
present
grams
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017555718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513204A5 (enExample
JP2018513204A (ja
Inventor
マーク シー． フォークナー
マーク シー． フォークナー
ドナルド ダブリュ． ミラー
ドナルド ダブリュ． ミラー
グラント エム． ハッチ
グラント エム． ハッチ
Original Assignee
ビレオ システムズ インコーポレイテッド
ビレオ システムズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビレオ システムズ インコーポレイテッド, ビレオ システムズ インコーポレイテッド filed Critical ビレオ システムズ インコーポレイテッド
Publication of JP2018513204A publication Critical patent/JP2018513204A/ja
Publication of JP2018513204A5 publication Critical patent/JP2018513204A5/ja
Priority to JP2021078285A priority Critical patent/JP2021120388A/ja
Application granted granted Critical
Publication of JP6882191B2 publication Critical patent/JP6882191B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2017555718A 2015-04-20 2016-04-20 神経保護および神経変性の治療のための組成物および方法 Active JP6882191B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021078285A JP2021120388A (ja) 2015-04-20 2021-05-06 神経保護および神経変性の治療のための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562150113P 2015-04-20 2015-04-20
US62/150,113 2015-04-20
US15/133,501 2016-04-20
PCT/US2016/028357 WO2016172148A1 (en) 2015-04-20 2016-04-20 Compositions and methods for neuroprotection and treatment of neurodegeneration
US15/133,501 US10245245B2 (en) 2015-04-20 2016-04-20 Compositions and methods for neuroprotection and treatment of neurodegeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021078285A Division JP2021120388A (ja) 2015-04-20 2021-05-06 神経保護および神経変性の治療のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2018513204A JP2018513204A (ja) 2018-05-24
JP2018513204A5 JP2018513204A5 (enExample) 2019-03-14
JP6882191B2 true JP6882191B2 (ja) 2021-06-02

Family

ID=57128180

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017555718A Active JP6882191B2 (ja) 2015-04-20 2016-04-20 神経保護および神経変性の治療のための組成物および方法
JP2021078285A Pending JP2021120388A (ja) 2015-04-20 2021-05-06 神経保護および神経変性の治療のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021078285A Pending JP2021120388A (ja) 2015-04-20 2021-05-06 神経保護および神経変性の治療のための組成物および方法

Country Status (7)

Country Link
US (3) US10245245B2 (enExample)
EP (1) EP3285755B1 (enExample)
JP (2) JP6882191B2 (enExample)
CA (1) CA2983151C (enExample)
ES (1) ES2903136T3 (enExample)
PL (1) PL3285755T3 (enExample)
WO (1) WO2016172148A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021120388A (ja) * 2015-04-20 2021-08-19 ビレオ システムズ インコーポレイテッド 神経保護および神経変性の治療のための組成物および方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11154499B2 (en) 2018-03-27 2021-10-26 Thermolife International, Llc Creatine and/or creatinine compositions and related methods
US20190298667A1 (en) * 2018-03-27 2019-10-03 Thermolife International, Llc Creatine and/or creatinine compositions and related methods
WO2020264412A1 (en) * 2019-06-28 2020-12-30 Thermolife International, Llc Compositions for creatine supplementation in creatine non-responders
WO2022109465A1 (en) * 2020-11-23 2022-05-27 Vireo Systems, Inc. Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535104T2 (de) 1994-11-08 2007-02-08 Avicena Group, Inc., Cambridge Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose
EP1363509B1 (en) * 2001-03-02 2006-10-11 The Howard Foundation Compositions containing creatine and creatinine
US7608641B2 (en) 2003-05-15 2009-10-27 Board Of Regents Of The University Of Nebraska Creatine oral supplementation using creatine hydrochloride salt
US8354450B2 (en) 2003-05-15 2013-01-15 Vireo Systems, Inc. Creatine oral supplementation using creatine hydrochloride salt
WO2006138261A2 (en) 2005-06-13 2006-12-28 Stratagene California System and method for fluorescence excitation and detection having distinct optical paths
EP2468272A1 (en) 2006-05-11 2012-06-27 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
US7683043B2 (en) * 2006-06-06 2010-03-23 Xenoport, Inc. Creatine phosphate analog prodrugs, compositions and uses thereof
AU2008261094B2 (en) * 2007-06-05 2014-07-17 Cryxa Llc Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine
US8445466B2 (en) * 2010-04-08 2013-05-21 John H. Owoc Stable aqueous compositions comprising amide-protected bioactive creatine species and uses thereof
US20150164847A1 (en) * 2013-12-16 2015-06-18 Vireo Systems, Inc. Method and composition for treating osteoarthritis
PL3285755T3 (pl) * 2015-04-20 2022-02-21 Vireo Systems, Inc. Chlorowodorek kreatyny do leczenia choroby Huntingtona

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021120388A (ja) * 2015-04-20 2021-08-19 ビレオ システムズ インコーポレイテッド 神経保護および神経変性の治療のための組成物および方法

Also Published As

Publication number Publication date
ES2903136T3 (es) 2022-03-31
US20200316000A1 (en) 2020-10-08
JP2021120388A (ja) 2021-08-19
JP2018513204A (ja) 2018-05-24
CA2983151C (en) 2024-03-05
US20190224151A1 (en) 2019-07-25
EP3285755A1 (en) 2018-02-28
EP3285755B1 (en) 2021-10-13
CA2983151A1 (en) 2016-10-27
WO2016172148A1 (en) 2016-10-27
PL3285755T3 (pl) 2022-02-21
US11160776B2 (en) 2021-11-02
US10583105B2 (en) 2020-03-10
US20160303061A1 (en) 2016-10-20
US10245245B2 (en) 2019-04-02
EP3285755A4 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
US11160776B2 (en) Compositions and methods for neuroprotection and treatment of neurodegeneration
ES2640777T3 (es) Terapia anaplerótica para la enfermedad de Alzheimer
JP2023040211A (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
US20120289492A1 (en) Methods of treating mitochondrial disorders using metalloporphyrins
EP2444078B1 (en) Use of amides of mono and dicarboxylic acids in the treatment of renal diseases
EP2555771B1 (fr) Compositions pharmaceutiques fortement dosees en biotine
BR112019011334A2 (pt) uso de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona e seus sais
BR112021015466A2 (pt) Materiais e métodos para tratar uma doença neurodegenerativa
JP7279958B2 (ja) 神経変性疾患の予防又は治療薬
US20230346759A1 (en) Novel therapeutic uses of compounds for enhancing mitochondrial function and treating mitochondrial diseases
US20220008388A1 (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
CN112888436A (zh) Tca循环中间体和其使用方法
US20250235413A1 (en) Modified forms of ambroxol for therapeutic use
ES2814048B2 (es) Uso combinado de biotina y tiamina en el tratamiento de la enfermedad de huntington
US20110166230A1 (en) Method of treating a human being for a class of neurological defects and seizure disorders
WO2023230560A1 (en) Treatment of organic acidemias or pantothenate kinase associated neurodegeneration with modulators of pantothenate kinases
WO2024229096A1 (en) Modified forms of ambroxol for therapeutic use
WO2017113775A1 (zh) 甘油三酯类化合物在制备治疗神经退行性疾病药物中的应用
US9399031B2 (en) Combined use of amides of mono- and dicarboxylic acids and silymarin in the treatment of renal diseases
CN117653642A (zh) 格列本脲促进nad+水平的用途
WO2025131275A1 (en) (2-(4-(1-(benzo[d]thiazol-5-yl)ethyl)piperazin-1 -yl)pyrimidin-5-yl)(imino)(methyl)-lamda6-sulfanone for use in the treatment of colitis, parkinson disease, tauopathy, als and alzheimer's disease
JPWO2005072721A1 (ja) 局所脳血流低下に伴う神経系障害の予防または治療のための医薬組成物
JP2022523308A (ja) ミトコンドリア病の治療における使用のためのカンナビジオールおよび／またはその誘導体
KR20050031499A (ko) 뇌허혈성 질환의 예방 및 치료용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171101

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201102

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210506

R150 Certificate of patent or registration of utility model

Ref document number: 6882191

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250